On Nov 07, major Wall Street analysts update their ratings for $Amicus Therapeutics (FOLD.US)$, with price targets ranging from $15 to $20.
Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and adjusts the target price from $18 to $17.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and maintains the target price at $15.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $20.
Needham analyst Gil Blum maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Amicus Therapeutics (FOLD.US)$'s main analysts recently are as follows:
Amicus' third-quarter revenues surpassed expectations, with notable sales from Galafold and purchase orders. Following these results, updates have been made to the quarterly model along with the updated guidance. Additionally, adjustments have been made to the cost of goods sold to align with management's comments on previously expensed inventory for P+O.
Here are the latest investment ratings and price targets for $Amicus Therapeutics (FOLD.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.